TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Risk Reduction in Coronary Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* acute myocardial infarction, CABG or PCI~Exclusion Criteria:~* Age \< 18 and age \> 80~* pregnant~* critical illness~* drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Multifactorial intervention (Type: ACTIVE_COMPARATOR): Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
- Control (Type: NO_INTERVENTION): no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Management of Pain Associated With Failed Back Surgery Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Previous spine surgery and subsequent chronic back pain~Exclusion Criteria:~* Patients with connective tissue diseases~* Patients with psychiatric illnesses

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pregabalin (Type: ACTIVE_COMPARATOR): A dose of 75 mg of Pregabalin twice daily for one month will be prescribed to each patient enrolled this study arm
- Gabapentin (Type: ACTIVE_COMPARATOR): A dose of 300 mg of Gabapentin twice daily for one month will be prescribed to each patient enrolled this study arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Meets 1 of the following criteria:~  * Histologically and/or cytologically confirmed stage IV adenocarcinoma of the breast (patient)~ * No diagnosis of an abnormal breast biopsy (including atypical ductal or lobular hyperplasia), or new diagnosis of breast cancer or breast cancer recurrence within the past five years (healthy participant)~* Evidence of disease progression AND initiating a new systemic treatment regimen with trastuzumab (Herceptin®), chemotherapy, endocrine therapy, or investigational agent(s) (patient)~  * Treatment may be given as a single agent or in combination~* Measurable or evaluable disease (patient)~  * Measurable disease is defined as ≥ 1 measurable lesion identified by RECIST criteria~ * Patients with evaluable disease only must have ≥ 1 tumor marker (e.g., carcinoembryonic antigen, CA 27-29, or CA 15-3) above normal level~* Treated brain metastases (surgery or radiation therapy) allowed provided patient has evidence of disease stability or presence of other site(s) of measurable or evaluable disease (patient)~  * No leptomeningeal disease~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Female~* Menopausal status not specified~* ECOG performance status 0-2~* No known cancer within the past 5 years other than basal cell or squamous cell carcinoma of the skin and/or adequately treated cervical cancer (healthy participant)~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Prior therapy in the preoperative, adjuvant, and/or metastatic setting allowed~  * Any number of prior regimens in any setting allowed~* No prior radiation therapy to the only site of disease unless there is evidence of post-radiation disease progression~* No selective estrogen receptor modulator or aromatase inhibitor for breast cancer prevention or therapy within the past 12 months (healthy participant)~* Prior or concurrent use of raloxifene for osteopenia or osteoporosis therapy allowed (healthy participant)~* Concurrent participation in another clinical trial, including one involving an investigational agent(s), allowed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Metastatic breast cancer patients (Type: None): DNA methylation analysis, microarray analysis, polymerase chain reaction, laboratory biomarker analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 4-6 years inclusive on the day of inclusion~* Child having completed the three-dose vaccination and the booster vaccination with DTacP-IPV//PRP\~T combined vaccine (PENTAXIM™) of the study E2I34~* Informed consent form signed by the parent(s) or other legal representative~* Able to attend all scheduled visits and to comply with all trial procedures~Exclusion Criteria :~* Participation in another clinical trial in the 4 weeks preceding the trial inclusion~* Planned participation in another clinical trial during the present trial period~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy~* Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion~* Blood or blood-derived products received in the past or current or planned administration during the trial (including immunoglobulins)~* Any vaccination in the 4 weeks preceding the trial vaccination~* History of diphtheria, tetanus, pertussis, poliomyelitis infection (confirmed either clinically, serologically or microbiologically)~* Clinical or known serological evidence of systemic illness including Hepatitis B, Hepatitis C and/or Human immunodeficiency virus (HIV) infection~* Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis diseases infection with the trial vaccine or another vaccine after completion of previous study E2I34~* Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination~* History of/current major neurological diseases or seizures~* Febrile illness (temperature ≥ 38°C) or acute illness on the day of inclusion.~* Serious or severe reaction after a previous dose of any vaccine containing pertussis antigen, such as~* encephalopathy (with or without convulsions) in the 7days following previous administration of a pertussis containing vaccine,~* temperature more than 39.5°C within 48 hours following vaccine injection, not due to another identifiable cause~* inconsolable crying equal or more than 3 hours within 48 hours following vaccine injection,~* hypotonic hyporesponsive episode within 48 hours following vaccine injection,~* seizures with or without fever within 3 days following vaccine injection.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- Study Group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Sciatic Block (SNB) Combined With a Continuous Femoral Block (CFNB) on Pain Scores After Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral total knee replacement~Exclusion Criteria:~* Contra-indication for general anesthesia~* Infection on puncture site~* Coagulation disorders~* Pre-existent neuropathies~* Allergies to local anesthetics, paracetamol, diclofenac and tramadol~* Severe dyspepsia~* Less than 50kg weigh~* Body Mass Index (BMI) greater than 40~* American Society of Anesthesiologists (ASA) Physical Status 4 or 5~* Absence of capacity to use the Visual Analog Score (VAS) scale~* Refusal to give informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous femoral nerve block (CFNB) (Type: ACTIVE_COMPARATOR): A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
- Single shot SNB plus CFNB (Type: EXPERIMENTAL): A single shot sciatic nerve block (SNB) is performed before surgery with 25ml of 0.2% ropivacaine in addition to the continuous femoral nerve block (CFNB) performed in the control group before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in Post anesthesia care unit (PACU) and maintained for 48h

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of SDN-037

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be at least 2 years of age on the date of assent or 18 years of age at the date of consent~2. Be able and willing to follow study instructions and complete all required visits~3. Females of childbearing potential must not be pregnant (as confirmed by a negative urine pregnancy test~4. Able to self-instill the IP or have a caregiver available to instil all doses of the IP~Exclusion Criteria:~1. Any known allergy or hypersensitivity to difluprednate therapy~2. An acute ocular infection (bacterial, viral or fungal) or active ocular inflammation in the study eye~3. Any active corneal pathology noted in the study eye~4. Currently suffering from alcohol and/or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SDN-037 (Type: EXPERIMENTAL): None
- vehicle (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute myeloid leukaemia (AML) according to WHO classification (\> 20% myeloblasts in peripheral blood or bone marrow at initial diagnosis) with \< 5% myeloblast in the bone marrow, indicated for allogeneic transplantation~* Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor (MUD) HLA-identity defined by the following markers: A, B, DRB1, DQB1.~* Target graft size (unmanipulated)~* bone marrow: 2 - 10 x 106 CD34+ cells/kg BW recipient or \> 2 x 108 nucleated cells/kg BW recipient or~* peripheral blood: 4 - 10 x 106 CD34+ cells/kg BW recipient~* Age \> 18 and \< 60 years~* Karnofsky Index \> 80 %~* Adequate contraception in female patients of child-bearing potential~* Written informed consent~Exclusion Criteria:~* Therapy related secondary AML~* AML with t(8;21)(q22;q22) in CR1~* Acute promyelocytic leukaemia with t(15;17)(q22;q12) in CR1~* Secondary malignancies~* Previous allogeneic transplantation~* Severe concomitant illnesses / medical conditions (e.g. impaired respiratory and/or cardiac function)~* Known and manifested malignant involvement of the CNS~* Active infectious disease~* HIV- positivity or active hepatitis infection~* Impaired liver function (Bilirubin \> upper normal limit; Transaminases \> 3.0 x upper normal limit)~* Impaired renal function (Creatinine-clearance \< 60 ml/min; Serum Creatinine \> 1.5 x upper normal limit).~* Pleural effusion or ascites \> 1.0 L~* Pregnancy or lactation~* Known hypersensitivity to treosulfan and/or fludarabine~* Participation in another experimental drug trial within 4 weeks before day -6~* Non-co-operative behaviour or non-compliance~* Psychiatric diseases or conditions that might impair the ability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Treosulfan (Type: EXPERIMENTAL): Patients with acute myeloid leukaemia (AML) according to WHO classification (\> 20% myeloblasts in peripheral blood or bone marrow at initial diagnosis) with \< 5% myeloblasts in the bone marrow, indicated for allogeneic transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Total Intravenous Anesthesia in Sinus Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing endoscopic sinus surgery~* Advanced inflammatory sinus disease, defined as allergic fungal sinusitis, chronic rhinosinusitis with nasal polyposis, chronic rhinosinusitis with eosinophilia, or rhinosinusitis with pan-sinus opacification (Lund-Mackay score \>12).~Exclusion Criteria:~* Noninflammatory sinonasal disease~* Disease extending through the skull base or orbital wall~* American Society of Anesthesiologists Preoperative Health Status \>II~* Known non-pharmacologic coagulopathy (platelet \< 50000/mL, international normalized ratio \> 1.2)~* Preoperative anticoagulants within 7 days of surgery~* Allergy to one of the study medications~* Age under 18 years~* Non-English-speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Total Intravenous (Type: EXPERIMENTAL): Intravenous propofol for maintenance of anesthesia
- Inhaled Anesthetic (Type: ACTIVE_COMPARATOR): Inhaled volatile anesthetic for maintenance of anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 2-Week Study In People With Nonalcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* controlled attenuation parameter greater than or equal to 260 dB/m via FibroScan~* liver fat greater than or equal to 6% via MRI~Exclusion Criteria:~* Chronic liver disease~* Type 2 diabetes requiring drug treatment~* Unable to undergo MRI~* History of heart attack or stroke

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- PF-06865571 100 mg (Type: EXPERIMENTAL): None
- PF-06865571 600 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Ketamine vs Morphine for Vaso-occlusive Crisis in Sicklers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 7-18 years~* sickle cell anemia patient with severe acute painful crisis~* Parental consent and child assent where applicable~Exclusion Criteria:~* Oxygen saturations below 90% on initial assessment~* Altered conscious and mental state that hinders communication~* Current enrollment in another clinical trial involving an investigational drug.~* History of a stroke~* Hypertension,~* Increased intracranial pressure.~* Glaucoma,~* Failed/ Difficult IV access

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Low dose ketamine (Type: EXPERIMENTAL): Low dose ketamine 1mg/kg given as an IV infusion via syringe pump over 10 minutes. Maximum of 2 doses to be given during study period that will last 2 hours.
- Morphine (Type: ACTIVE_COMPARATOR): Morphine 0.1mg/kg given as an IV infusion via a syringe pump over 10 minutes. Maximum of 2 doses to be given during the study period that will last 2 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Male or female recipients of a full-size liver allograft, aged 18 to 65 years.~Exclusion criteria:~Patients with thrombocytopenia (platelets \<50,000/mm³), with an absolute neutrophil count of \<1,000/mm³ or leucopenia (leucocytes \<2000/mm³), with anemia with Hb \< 6g/dl at time of randomization~Patients with uncontrolled hypercholesterolemia (\>350mg/dL; \>9mmol/L) or hypertriglyceridemia (\>750 mg/dL; \>8.5 mmol/L) at time of randomization~History of malignancy of any organ system within the past 5 years whether or not there is evidence of local recurrence or metastases, other than non-metastatic basal or squamous cell carcinoma of the skin or HCC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- EVR/TAC (Type: EXPERIMENTAL): Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: \< 5 ng/mL)
- TAC (Type: ACTIVE_COMPARATOR): Tacrolimus (C0-h: 6-10 ng/ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cervical Cancer Screening Intervention Among Korean American Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identified Korean ethnicity~* Possessing a functional telephone in the home or on person~* Anticipated presence in this geographic region for a period of one year~Exclusion Criteria:~* A current diagnosis of cervical cancer~* Have had a Pap test within the past 12 months~* Are currently adherent to doctor recommended screening interval

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Culturally appropriate intervention (Type: EXPERIMENTAL): Culturally appropriate, church-based intervention focused on cervical cancer and navigation assistance.
- General health education control (Type: ACTIVE_COMPARATOR): General health and cancer education on nutrition, regular check-ups, tobacco use, and cancer screening.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Good general health as judged by the investigator, based on medical history, physical examination, electrocardiogram (ECG), vital signs and clinical laboratory~* Body mass index (BMI) of 18.5-30.0 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Males who are sexually active and not surgically sterilised, who or whose partner(s): a. are not using adequate contraceptive methods (e.g. condom with spermicidal foam/gel/film/cream or contraceptives with a Pearl Index below 1%, such as implants, injectables, combined oral contraceptives, or hormonal intrauterine devices or diaphragm + spermicide) or b. do not refrain from sexual intercourse during the trial and until 30 days following the last dose of trial medication. In addition, subjects must not donate sperm for the duration of the trial and for 30 days following the last dose of trial medication or c. sterilization of either partner~* Suffer from a life threatening disease or has a history of any clinically significant disease or disorder~* History of acute idiopathic or chronic pancreatitis~* Calcitonin value equal to or above 50 ng/L~* Any clinically significant abnormal laboratory test results (haematology, biochemistry and urinalysis), as judged by the investigator and any of the following laboratory safety results (based on screening results): Amylase, lipase and creatinine, above upper normal range. Aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT) and gamma-glutamyl-transpeptidase (gamma-GT) above 1.5 times upper normal range (UNR). Thrombocytes below 0.75 times lower normal range (LNR) or above 1.25 times UNR. Leucocytes outside 3.0 to 11.0x10\^9/L (normal range is 3.91 to 8.77x10\^9/L. Sodium outside the range 130.0 to 150.0 mmol/L (normal range is 136-145 mmol/L). Potassium outside the range 3.0 to 5.5 mmol/L (normal range is 3.5 to 5.1 mmol/L)~* Any clinically significant abnormal ECG, as judged by the investigator~* Subjects who are smokers

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Post-dose fasting 120 mins/50 ml water (Type: EXPERIMENTAL): None
- Post-dose fasting 60 mins/50 ml water (Type: EXPERIMENTAL): None
- Post-dose fasting 30 mins/50 ml water (Type: EXPERIMENTAL): None
- Post-dose fasting 15 mins/50 ml water (Type: EXPERIMENTAL): None
- Post-dose fasting 120 mins/120 ml water (Type: EXPERIMENTAL): None
- Post-dose fasting 60 mins/120 ml water (Type: EXPERIMENTAL): None
- Post-dose fasting 30 mins/120 ml water (Type: EXPERIMENTAL): None
- Post-dose fasting 15 mins/120 ml water (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete